Canal-U

Mon compte

Résultats de recherche

Nombre de programmes trouvés : 14779
Label UNT Conférences

le (14m5s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Resistant hypertension trials: Can renal denervation therapy lower blood pressure?Speaker: Felix MAHFOUD, Homburg, GERDiscussant: Michel AZIZI, Paris, FRAAbstract : Renal Denervation: Caution is still requiredDespite the availability of multiple classes of orally active antihypertensive treatments, resistant hypertension remains an important public health issue in 2012. The failure of purely pharmacological approaches to treat resistant hypertension has stimulated interest in invasive device-based treatments. A new catheter system using radiofrequency energy has been developed, allowing a percutaneous endovascular approach to renal denervation and providing patients with resistant hypertension with a new therapeutic option. ...
Voir la vidéo
Label UNT Conférences

le (7m22s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developments

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Barostim: Experience so far and future developmentsSpeaker: Hermann HALLER, Hannover, GERDiscussant: Nadim YARED, CVRx, USAAbstract : Barostim: Experience so far and future developmentsL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 HYPERTENSION TRIALIST WORKSHOP: AUTONOMIC MODULATION THERAPYChairpersons: George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NORResistant hypertension is usually defined as uncontrolled hypertension despite the intake of at least 3 antihypertensive drugs in full doses including a diuretic. Most investigators would ...
Voir la vidéo
Label UNT Conférences

le (11m50s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trials

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trialsSpeaker: Faiez ZANNAD, Nancy, FRADiscussant: Gaetano DE FERRARI, Pavia, ITAAbstract : Autonomic modulation therapy for heart failure: Preclinical data and ongoing trialsL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 HYPERTENSION TRIALIST WORKSHOP: AUTONOMIC MODULATION THERAPYChairpersons: George BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NORResistant hypertension is usually defined as uncontrolled hypertension despite the intake of at least 3 antihypertensive drugs ...
Voir la vidéo
Label UNT Conférences

le (8m38s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : What are relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval and reimbursement What kind of evidence is needed and the level is somewhat clear. Obviously, ...
Voir la vidéo
Label UNT Conférences

le (19m43s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementL’auteur n’a pas transmis de conflit ...
Voir la vidéo
Label UNT Conférences

le (4m14s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursement

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementInvestigator viewpoint: George BAKRIS, Chicago, USA - Ileana PIÑA, New York, USARegulatory viewpoint: Andrew FARB, FDA, USAIndustry viewpoint: Rob KIEVAL, CVRx, USA - Kenneth STEIN, Boston Scientific, USAAbstract : Debate : What relevant endpoints in autonomic nerve modulation therapy trials? What kind/level of evidence? Targets to meet for approval (FDA, and in EU, beyond CE mark) and reimbursementL’auteur n’a pas transmis de conflit ...
Voir la vidéo
Label UNT Conférences

le (7m28s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusion

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : conclusionGeorge BAKRIS, Chicago, USA - Sverre E. KJELDSEN, Oslo, NORAbstract : conclusionL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Réalisation, production : Canal U/3S et CERIMESKeyword : Cardiovascular Clinical Trialists, Paris, 2012, Cardiovascular prevention, cardiovascular pharmacology, modulation therapy
Voir la vidéo
Label UNT Conférences

le (13m57s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.• NICESpeaker: Suzanna HARDMAN, London, GBR• German CHF registry: REFLECT –HFSpeaker: Carsten TSCHOEPE, Berlin, GER• Eurobservational, the ESC Heart failure RegistrySpeaker: Aldo MAGGIONI, Florence, ITAAbstract : National guideline implementation and national registries : German CHF registry: REFLECT –HFL’auteur n’a pas transmis de conflit d’intérêt concernant les données diffusées dans cette vidéo ou publiées dans la référence citée.9th Global Cardiovascular Clinical Trialists Forum • Paris 2012 Multidisciplinary expert workshop : achievements challenges and barriers to implantation of the ESC 2012 chronic heart failure guidelines.Chairpersons: Alain COHEN-SOLAL, Paris, ...
Voir la vidéo
Label UNT Conférences

le (29m25s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries.

Title : Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 : National guideline implementation and national registries• NICESpeaker: Suzanna HARDMAN, London, GBR• German CHF registry: REFLECT –HFSpeaker: Carsten TSCHOEPE, Berlin, GER• Eurobservational, the ESC Heart failure RegistrySpeaker: Aldo MAGGIONI, Florence, ITAAbstract : Multidisciplinary expert workshop: achievements, challenges and barriers to implementations of the ESC 2012 chronic heart failureEurobservational Research Program, the ESC Heart Failure Long Term RegistryChronic Heart Failure (HF) is associated with a high burden of mortality and morbidity, reduced quality of life, and increasing healthcare costs in both US and Europe. Evidence-based medicine represents the most effective means of ensuring ...
Voir la vidéo
Conférences

le (1h6m55s)

Cardiovascular Clinical Trialists (CVCT) Forum – Paris 2012 - Workshop 5 : Identifying new targets: The value of omics and mendelian randomization studies (Daniel SWERDLOW)

MODIGLIANI Workshop 5 - Saturday December 1st, 2012THE ATHEROSCLEROSIS TRIALISTS FORUMChairpersons: Wolfgang KOENIG, Ulm, GER - Anthony WIERZBICKI, London, GBRWebcast: Tabassome SIMON, Paris, FRAWill new compounds be able to reduce the residual risk in high risk patients when treatment targets based on new ESC guidelines have been achieved (e.g. LDL-C < 70mg/dl)?Despite widespread early intervention in acute coronary syndromes and complete revascularization of stenotic lesions complemented by aggressive polypharmacotherapy, still a high percentage of patients develop a secondary event.This has been shown in various registries and recent data from the GRACE registry have suggested that we grossly underestimate long-term risk ...
Voir la vidéo

 
FMSH
 
Facebook Twitter Google+
Mon Compte